TickerTalks
Browse all tickers →
TickerTalks›$PFE
PFPFE

Pfizer Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 5% YoY at strong margins3 insiders bought $3.0M in 30 daysConsistent chatter on X (657/wk), no spike
$PFE·$143B·Drug Manufacturers - General·Healthcare
$27.96-0.2%YTD+1.7%1Y+13.7%
Mentions · last 7 days
2026-08-20: 123 posts2026-08-21: 77 posts2026-08-22: 27 posts2026-08-23: 33 posts657-0%
Price updated 2d ago·X counts updated 7d ago
PFPFE
$PFEPfizer Inc.
$27.96-0.21%657 posts-0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $PFE, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptAcceleratingAI verdict · as of 2026-08-30

The move is getting stronger, with heavier trading behind it.

Boring big pharma with a fresh COVID-vaccine approval and — more interestingly — three officers just bought ~$1M each of stock open-market.

Pfizer is the mega-cap pharma still working through the post-COVID demand cliff, with a maturing pipeline and a maligned M&A track record. What makes right now different is a rare cluster of open-market insider buying, coincident with a genuine near-term catalyst.

Why the setup is worth attention:

  • The insider buying is unusually clean: CEO Albert Bourla, director Mortimer Buckley, and director Ronald Blaylock each open-market bought ~$1M in the current window — a real-cash cluster (not tax-withholding or option exercises) at 85% of the 52-week range is where such buys carry the most information.
  • The dated catalyst is real: the FDA just approved the 2026-27 COVID vaccine from Pfizer/BioNTech for the high-risk population, locking in a defensible revenue line into winter — smaller than peak years, still a multi-billion-dollar franchise.
  • The valuation is defensible: 20x earnings, 12x EV/EBITDA and a 6.4% FCF yield with a ~7% dividend on top — for a business earning a 23% operating margin, the market is pricing Seagen-style skepticism, and any pipeline win compresses that discount.
  • The pipeline is showing life: the NVCT + PFE Lorla ALK combo trial is recruiting; the minority M&A worry (Seagen, Metsera) is fair and pipeline data would blunt it.

The November 3 print sets the tone — a clean Seagen-integration update plus vaccine-season contribution keeps the rerate going; a pipeline setback or a guide cut breaks the setup and turns the insider buys into noise.

Agrees with X sentimentAgree — the crowd's 'generational run' framing is early but the underlying signal (FDA COVID vaccine approval + insider buying cluster + reasonable multiple) supports the direction; the minority M&A skepticism is fair and pipeline data is what would close that debate.

What to watch: November 3 earnings and any pipeline readouts (Lorla ALK combo, oncology franchise) — a clean update on Seagen integration plus vaccine season contribution keeps the rerate going; a pipeline setback breaks the setup and negates the insider buys.

On the calendar: 2026-11-03 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment25 posts analyzed · as of 2026-08-29

Pfizer sentiment on X is bullish, framed as an emerging generational-run setup. FDA approved the updated 2026-27 COVID vaccines from Pfizer/BioNTech/Moderna for adults 65+ and high-risk 5-64, and traders discuss PFE tightening above support with a gap-fill swing setup. NVCT + PFE Lorla ALK combo study launched and recruiting is treated as pipeline optionality. A minority questions Pfizer's M&A strategy following Seagen and Metsera underwhelming, but the base tone is 'starting a generational run.'

Read the AI verdict + X sentiment for $PFE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes vaccines, oncology drugs, and small-molecule medicines while rebuilding revenue after COVID product declines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $PFE.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $PFE

Neutral — Makes vaccines, oncology drugs, and small-molecule medicines while rebuilding revenue after COVID product declines; limited read-through from drug manufacturers - general macro dynamics to this specific revenue mix.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+47.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
19.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
8.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
23.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
8.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
69.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$0.77$0.68+12.9%
Q1 2026May 5, 2026$0.75$0.72+3.9%
Q4 2025Feb 3, 2026$0.66$0.57+16.4%
Q3 2025Nov 4, 2025$0.87$0.63+37.4%
Next earningsTue, Nov 3·consensus EPS $0.79

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$14.5B+5.4%67.3%27.9%$0.47$2.2B
Q4 FY25$17.6B-1.2%70.0%21.0%$-0.29$4.5B
Q3 FY25$16.7B-5.9%74.9%21.3%$0.62$4.0B
Q2 FY25$14.7B+10.3%64.3%24.4%$0.51$-1.2B

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$61.8B$60.7B – $62.6B$2.94$2.84 – $3.0318
FY27$59.3B$57.2B – $60.8B$2.84$2.61 – $3.0018
FY28$54.7B$51.7B – $58.4B$2.44$1.58 – $2.7821
FY29$53.4B$51.2B – $55.5B$2.30$2.18 – $2.4210
FY30$53.8B$51.6B – $55.9B$2.35$2.22 – $2.4710

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.85%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+9.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+7.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 5.7B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.285-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Cluster buy3 insiders bought shares in the last 30 days.

Recent transactions

BuyAug 12Albert BourlaCEO38.0K sh$1.0MSellAug 5Jennifer B. DamicoSVP & Controller3.3K sh$83KBuyAug 5Mortimer J BuckleyDirector37.6K sh$960KBuyAug 5Ronald E BlaylockDirector39.2K sh$999KSellJun 9Jennifer B. DamicoSVP & Controller2.0K sh$51K
+ 48 other (47 awards · 1 inkind) in window

See when $PFE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJun 188-K — Item 7.01: Press release / Reg FD
AI summary

Pfizer reaffirmed its full-year 2026 financial guidance on June 18, 2026, concurrent with the CFO departure announcement. Guidance is unchanged: revenues of $59.5–$62.5 billion and Adjusted Diluted EPS of $2.80–$3.00, consistent with the December 2025 introduction and May 5, 2026 Q1 call reaffirmation. The same-day guidance reaffirmation alongside the CFO transition is designed to signal management confidence in the financial outlook and contains investor concern from the leadership change. Stable outlook — Pfizer is holding guidance range despite a CFO departure mid-year.

8-KOfficer or director changeJun 188-K — Item 5.02: Officer or director change
AI summary

Pfizer CFO Dave Denton notified the company on June 16, 2026 that he will resign effective August 15, 2026 to pursue a role in consumer goods outside pharmaceuticals, with no disagreement over Pfizer's financial or operating results. Cecile Guegan (55), SVP Finance, Global Biopharmaceutical Business (Pfizer since 2005, current role since 2022), will serve as Interim CFO from August 16, 2026 while a comprehensive permanent search is conducted. A CFO departure mid-year is material for a large-cap pharma navigating post-COVID product portfolio transitions; the same-day guidance reaffirmation (see companion 8-K) was filed simultaneously to offset investor concern.

3/ANew insider — initial holdingsApr 273/A
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3/A (amended) for PFE on 2026-04-27, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KShareholder voteApr 278-K — Item 5.07: Shareholder vote
AI summary

PFE held its Annual Meeting of stockholders around 2026-04-27 (8-K Item 5.07). Stockholders elected 11 directors to the board. Independent auditor ratification was approved. Routine governance event — monitor for unusually high withhold votes as an activist signal.

3New insider — initial holdingsApr 103
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for PFE on 2026-04-10, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

+ 15 other (3 13Gs · 2 13Fs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Archer Investment Corp Acquires Shares of 73,546 Pfizer Inc. $PFEdefenseworld.net·1d agoBioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat247wallst.com·2d agoUS FDA approves updated COVID vaccines for 2026-27 seasonreuters.com·3d agoPfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccineglobenewswire.com·3d agoPfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccinebusinesswire.com·3d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRK$LLY$NVO$JNJ$GILD$ABBV$AMGN$AZN
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport